Renoprotection with antihypertensive effect by inhibition of rennin - angiotensin system

Authors

  • Mohd Urooj Regional Research Institute of Unani Medicine MOH Aligarh India
  • Monika Tandon Department of Clinical Pharmacology Unit, Ranbaxy Laboratories Ltd, India
  • Sunil S. Iyer Department of Clinical Pharmacology & Pharmacokinetic Unit Ranbaxy Laboratories Ltd, India

Keywords:

Chronic kidney disease, Renin angiotensin system, Angiotensin receptors blocker. Angiotensin-converting enzyme inhibitor

Abstract

Hypertension is a common cause of chronic kidney disease (CKD) and even more common sequelae of CKD. It is essential to preserve renal function while controlling blood pressure. There is growing evidence that reduction and normalization of proteinuria is a key treatment goal for renal protection. Several clinical studies, mainly but not exclusively in diabetic patients were reviewed, subsequently suggested that anti-hypertensive agents inhibiting the renin– angiotensin system (RAS), such as angiotensin converting enzyme inhibitors (ACEIs) or angiotensin II type 1 receptor blockers (ARBs), achieved better renoprotection than other anti-hypertensive drugs. Inhibition of the renin-angiotensin system (RAS), either by ACE inhibitors or angiotensin-Receptors blocker (ARB) slows the progression of CKD by reducing the level of proteinuria in the diabetic and non-diabetic CKD resulting in less renal structural damage.

Downloads

Published

2014-08-01

How to Cite

Mohd Urooj, Monika Tandon, & Sunil S. Iyer. (2014). Renoprotection with antihypertensive effect by inhibition of rennin - angiotensin system. World Journal of Pharmaceutical Sciences, 2(8), 871–874. Retrieved from https://wjpsonline.com/index.php/wjps/article/view/renoprotection-antihypertensive-inhibition-rennin-angiotensin

Issue

Section

Review Article

Most read articles by the same author(s)